ReviewAIMS neuroscience2022
Targeted delivery of gold nanoparticles by neural stem cells to glioblastoma for enhanced radiation therapy: a review.
Review in AIMS neuroscience, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Stem cell technology for antitumor drug loading and delivery in oncology.Oncology research · 2024Review
- Multipotent mesenchymal stromal/stem cell-based therapies for acute respiratory distress syndrome: current progress, challenges, and future frontiers.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica · 2024Review
- Nanoparticle Strategies to Improve the Delivery of Anticancer Drugs across the Blood-Brain Barrier to Treat Brain Tumors.Pharmaceutics · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glioblastoma (GB) is the most malignant subtype of brain cancer derived from astrocytes in the brain. Radiotherapy is one of the standard treatments for GB patients, but its effectiveness is often limited by the radioresistance of aggressive GB cells. Higher dose of radiation needs to be applied to GB patients to eliminate these stubborn cells, but this also means more side effects on the adjacent healthy cells because the radiation beam could indistinguishably harm all cells exposed to it. In order to address this problem, various strategies have been studied to enhance the radiosensitivity among the radioresistant cell populations for targeted eradication of GB without harming other surrounding healthy cells. One of the promising strategies for radiosensitization is to use gold nanoparticles (AuNPs) which can enhance photoelectric effects within the radioresistant cells for higher killing efficiency even at low doses of radiation. Nonetheless, there is no evidence showing the capability of these nanoparticles to travel to brain tumor cells, therefore, the application of this nanotechnology is very much dependent on the development of a suitable carrier to deliver the AuNPs to the GB tumor sites specifically. In this review article, we discussed the potentials of neural stem cells (NSCs) as biological carriers to carry AuNPs to targeted GB tumor sites and provided new insights into the potential of NSC-based targeted delivery system for GB treatment. The information reported here may pave a new direction for clinical transformation of next-generation nanoparticle-assisted radiotherapy to optimize the efficacy of radiotherapy for GB treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.